Patricia Carr Biography and Net Worth

Patricia Carr serves as Vice President, Finance and Principal Accounting Officer of the Company. Prior to that, from September 2011 to July 2012, she served as Vice President, Finance of Alkermes plc, a global biopharmaceutical company. From June 2002 to September 2011, she served in a number of roles in Elan Corporation, a neuroscience-based biotechnology company, most recently as Vice President, Finance.

What is Patricia Carr's net worth?

The estimated net worth of Patricia Carr is at least $878,217.06 as of March 15th, 2023. Ms. Carr owns 6,286 shares of Jazz Pharmaceuticals stock worth more than $878,217 as of March 21st. This net worth approximation does not reflect any other assets that Ms. Carr may own. Learn More about Patricia Carr's net worth.

How do I contact Patricia Carr?

The corporate mailing address for Ms. Carr and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected] Learn More on Patricia Carr's contact information.

Has Patricia Carr been buying or selling shares of Jazz Pharmaceuticals?

In the last ninety days, Patricia Carr has sold $297,876.54 of Jazz Pharmaceuticals stock. Most recently, Patricia Carr sold 1,023 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $133.22, for a transaction totalling $136,284.06. Following the completion of the sale, the chief accounting officer now directly owns 6,286 shares of the company's stock, valued at $837,420.92. Learn More on Patricia Carr's trading history.

Who are Jazz Pharmaceuticals' active insiders?

Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Bruce Cozadd (CEO), Patrick Enright (Director), Peter Gray (Director), Finbar Larkin (SVP), Seamus Mulligan (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), and Christopher Tovey (COO). Learn More on Jazz Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Jazz Pharmaceuticals?

During the last year, insiders at the specialty pharmaceutical company sold shares 40 times. They sold a total of 162,354 shares worth more than $24,122,859.21. The most recent insider tranaction occured on March, 15th when CAO Patricia Carr sold 1,023 shares worth more than $136,284.06. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.

Information on this page was last updated on 3/15/2023.

Patricia Carr Insider Trading History at Jazz Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2023Sell1,023$133.22$136,284.066,286View SEC Filing Icon  
3/5/2023Sell1,148$140.76$161,592.487,309View SEC Filing Icon  
12/5/2022Sell63$152.06$9,579.785,934View SEC Filing Icon  
8/15/2022Sell2,142$160.06$342,848.525,934View SEC Filing Icon  
5/11/2022Sell722$147.51$106,502.226,234View SEC Filing Icon  
5/9/2022Sell1,067$148.94$158,918.987,229View SEC Filing Icon  
8/6/2021Sell157$147.96$23,229.726,035View SEC Filing Icon  
12/4/2020Sell62$152.55$9,458.10View SEC Filing Icon  
8/12/2020Sell142$123.80$17,579.606,200View SEC Filing Icon  
8/7/2020Sell158$125.87$19,887.466,342View SEC Filing Icon  
6/5/2020Sell138$124.00$17,112.00View SEC Filing Icon  
3/12/2020Sell600$102.17$61,302.006,500View SEC Filing Icon  
3/9/2020Sell568$111.45$63,303.607,668View SEC Filing Icon  
3/6/2020Sell232$119.17$27,647.447,668View SEC Filing Icon  
3/3/2020Sell247$119.75$29,578.258,153View SEC Filing Icon  
12/5/2019Sell1,749$148.93$260,478.57View SEC Filing Icon  
See Full Table

Patricia Carr Buying and Selling Activity at Jazz Pharmaceuticals

This chart shows Patricia Carr's buying and selling at Jazz Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals logo
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $139.71
Low: $138.62
High: $140.78

50 Day Range

MA: $148.20
Low: $133.98
High: $157.77

2 Week Range

Now: $139.71
Low: $125.36
High: $169.98


393,854 shs

Average Volume

542,094 shs

Market Capitalization

$8.85 billion

P/E Ratio


Dividend Yield